Potential Cardiovascular Blockbuster Inclisiran Among New Filings At EMA
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.
You may also be interested in...
A number of advanced therapies are likely to be approved in the EU this year.
Companies are due to learn this week whether the European Medicines Agency will fast-track its review of their soon-to-be-filed EU marketing applications.
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.